Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Zealand Pharma - Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
GlobeNewswire

Company announcement No. 35 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 30, 2026) Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ('the Company' or “Zealand Pharma”) (Nasdaq: ZEAL)…

washingtonexaminer.com - Elbert Guillory - Trump is about to crash drug prices - and Big Pharma is terrified
Trump is about to crash drug prices - and Big Pharma is terrified
Washington Examiner

Less than a year ago, Pharmaceutical Research and Manufacturers of America (PhRMA) CEO Stephen Ubl stated PhRMA would be “answering Trump's call” to put America first in the healthcare ecosystem. However, as President Donald Trump…

globenewswire.com - Idorsia Pharmaceuticals Ltd - Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant
Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant
GlobeNewswire

Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region Allschwil, Switzerland – July 27, 2026 Idorsia Ltd (SIX: IDIA) has entered into an…

investors.com - HARRIET WEBER - This Stock Of The Day Dines On Big Pharma Royalties; Up 56% In 2026
This Stock Of The Day Dines On Big Pharma Royalties; Up 56% In 2026
Investor's Business Daily

Ligand Pharmaceuticals Ligand Pharmaceuticals LGND $ 294.12 $6.42 2.13% 6% IBD Stock Analysis Shares could rebound from 21-day exponential line, or possible form a flat base. If stock continues lower, watch for a rebound from the 50-day moving…

dailycaller.com - Ann Rodgers - Big Pharma Wants To Turn Toad Venom Into The Next Blockbuster Drug
Big Pharma Wants To Turn Toad Venom Into The Next Blockbuster Drug
The Daily Caller

Big Pharma is making a high-stakes bet that their next cash grab will come from an unlikely source: the psychedelic venom of toads. Pharmaceutical companies are pouring billions into a drug called 5-MeO-DMT, often known as bufo, a powerful…

theguardian.com - Jasper Jolly - AstraZeneca boss urges western drugmakers to move at 'Chinese speed'
AstraZeneca boss urges western drugmakers to move at 'Chinese speed'
The Guardian

AstraZeneca must operate at “Chinese speed” to ensure it doesn't suffer the fate of the western automotive industry by losing out to more innovative rivals, the drug company's boss has said. The FTSE 100 company is watching the rise…

marketbeat.com - Avalyn Pharma (NASDAQ:AVLN) Shares Gap Down - Time to Sell?
Avalyn Pharma (NASDAQ:AVLN) Shares Gap Down - Time to Sell?
MarketBeat

Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) gapped down before the market opened on Monday. The stock had previously closed at $29.73, but opened at $28.25. Avalyn Pharma shares last traded at $28.37, with a volume of 1,744 shares. Several…

thehindubusinessline.com - Stocks to watch on Monday: NBCC, NTPC, Aurobindo Pharma, Waaree Energies, Cyient, Dodla Dairy and more
Stocks to watch on Monday: NBCC, NTPC, Aurobindo Pharma, Waaree Energies, Cyient, Dodla Dairy and more
BusinessLine

NBCC (India) Ltd has bagged project management consultancy work orders aggregating to approximately ₹108.85 crore (excluding GST). The contracts were secured in the ordinary course of business from domestic government agencies across…

marketbeat.com - Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.2% - What's Next?
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.2% - What's Next?
MarketBeat

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) shares were down 5.2% on Monday. The stock traded as low as $18.32 and last traded at $18.32. Approximately 573 shares were traded during mid-day trading, a…

marketbeat.com - Orbimed Advisors LLC Buys 10,000 Shares of Ascendis Pharma A/S $ASND
Orbimed Advisors LLC Buys 10,000 Shares of Ascendis Pharma A/S $ASND
MarketBeat

Orbimed Advisors LLC increased its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.8% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 181,977 shares of the…

marketbeat.com - Troluce Capital Advisors LLC Invests $22.78 Million in Ascendis Pharma A/S $ASND
Troluce Capital Advisors LLC Invests $22.78 Million in Ascendis Pharma A/S $ASND
MarketBeat

Troluce Capital Advisors LLC acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 99,600 shares of the biotechnology company's stock…

seekingalpha.com - Edmund Ingham - argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX)
argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX)
Seeking Alpha

argenx SE is acquiring Forte Biosciences, Inc. for $2.2bn, paying a substantial premium to gain FB-102, a first-in-class anti-CD122 antibody. FB-102 offers clinical proof-of-concept in vitiligo and celiac disease, aligning with ARGX's strategy to…

thehindu.com - The Hindu Bureau - Merck inks pact with four generic drugmakers in India for HIV drug
Merck inks pact with four generic drugmakers in India for HIV drug
The Hindu

Pharma major Merck (known as MSD outside of the U.S. and Canada) has signed non-exclusive voluntary licensing agreements with generic drugmakers Aurobindo Pharma, Cipla, Emcure and Viatris in India to enable supply of its investigational…

afaqs.com - afaqs! news bureau - Novo Nordisk sues Eli Lilly over misleading ad claims
Novo Nordisk sues Eli Lilly over misleading ad claims
afaqs!

Novo Nordisk has taken Eli Lilly to court, accusing its rival of running advertising that unfairly makes its weight loss and diabetes drugs look more effective than Novo's own, as reported by Reuters. At the heart of the dispute is dosage. Novo…

cnbc.com - Michael Bloom - Here are Monday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, AMD, GM, Ford, Rivian & more
Here are Monday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, AMD, GM, Ford, Rivian & more
CNBC

Here are Monday's biggest calls on Wall Street: Piper Sandler upgrades Rivian and Mobileye to overweight from neutral Piper said both stocks are compelling. ' RIVN: a de-risked balance sheet, a smooth R2 ramp, and an improved demand outlook.....

Receive a Daily briefing on Pharma Industry News

Get Started